Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM
Authors:
- 16 September 2022
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 44 (10) , 1418-1426
Abstract
No abstract availableKeywords
Funding Information
- Kurume University
This publication has 28 references indexed in Scilit:
- Bile Acid Binding Resin Improves Metabolic Control through the Induction of Energy ExpenditurePLOS ONE, 2012
- TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid LoadingCell Metabolism, 2011
- Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of ObesityDiabetes, 2011
- Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind studyAlimentary Pharmacology & Therapeutics, 2011
- Improved Glycemic Control with Colesevelam Treatment in Patients with Type 2 Diabetes Is Not Directly Associated with Changes in Bile Acid MetabolismHepatology, 2010
- Leukotriene Signaling in Atherosclerosis and IschemiaCardiovascular Drugs and Therapy, 2008
- Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetesClinical Therapeutics, 2007
- Farnesoid X receptor is essential for normal glucose homeostasisJournal of Clinical Investigation, 2006
- Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1Biochemical and Biophysical Research Communications, 2005
- Identification of membrane-type receptor for bile acids (M-BAR)Biochemical and Biophysical Research Communications, 2002